ALS Platform Trial

The purpose of this platform trial is to evaluate the efficacy of multiple investigational drugs at once, as compared with a shared placebo group, on ALS disease progression. New treatment regimens (drugs) will be added as they become available within the trial, meaning that multiple drug treatment regimens may be ongoing at all times during the platform trial. The placebo-controlled treatment period may last up to 36 weeks. After that, an optional active treatment extension period may be added per each separate regimen after completion of the placebo-controlled treatment period.

Principal Investigator:
Shafeeq Ladha, MD

Enrollment Contact:
Whitney Dailey
(602) 406-7804
Fulton.Research@CommonSpirit.org